The European Commission (EC) has granted Diovan (valsartan) a new paediatric indication for the treatment of hypertension in children and adolescents six to 18 years of age. Following the commission's decision, the paediatric indication needs to be implemented through EU National Competent Authorities before Diovan will be available for paediatric use across the European Union (EU), both in the existing tablet formulations as well as a newly developed oral solution.
Following national implementation across the EU, Novartis intends to apply for a six-month exclusivity extension of the protection for valsartan (the active ingredient in Diovan), in line with the European Paediatric Regulation.
Evidence suggests that there are in fact more cases of paediatric high blood pressure in the EU than previously thought. While the total number of children with high blood pressure in the EU is unknown, data from various EU countries suggest an average prevalence rate of up to 11 per cent. European Society of Hypertension (ESH) guidelines emphasize that high blood pressure in childhood and adolescence increases the risk of developing the condition in adulthood, which can subsequently lead to an increased risk of cardiovascular disease and damage to vital organs such as the heart and kidney.
"We are seeing an increasing number of children and adolescents being diagnosed with high blood pressure, a trend largely the result of the growing number of young people who are overweight or obese," said Franz Schaefer, professor of Paediatrics and chief of the Paediatric Nephrology Division, Heidelberg University Hospital, Germany. "The only way to help reduce the impact of this condition in this patient group is to improve the identification and treatment of it."
Diovan was also approved for paediatric use in the United States by the Food and Drug Administration (FDA) in December 2008, for the treatment of children aged 6-16 years with high blood pressure.
Diovan is the world's number one selling high blood pressure medication. It provides the flexibility of a wide range of single-pill combinations and dosing options, all with the convenience of a once-daily treatment schedule. These include Co-Diovan (valsartan/hydrochlorothiazide), Exforge (valsartan/amlodipine) and Exforge HCT (valsartan/amlodipine/hydrochlorothiazide).
In addition to the valsartan family of products, the Novartis portfolio of cardiovascular and metabolic medications for the treatment of high blood pressure and diabetes includes the first and only approved direct renin inhibitor, Rasilez (aliskiren), and its single-pill combination formulations, Rasilez HCT (aliskiren/hydrochlorothiazide) and Valturna (aliskiren/valsartan); and Galvus (vildagliptin) and Eucreas (vildagliptin/metformin) for the treatment of type 2 diabetes.